LENZ Therapeutics Announces Positive Topline Data from Aceclidine Phase 3 CLARITY Presbyopia Trials

SAN DIEGO--(BUSINESS WIRE) April 03, 2024 -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or“LENZ” or the“Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials